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Benign breast disease (BBD) is a strong breast cancer risk factor but identifying patients 
that might develop invasive breast cancer remains a challenge.  
Methods 
By applying machine-learning to digitized H&E-stained biopsies and computer-assisted 
thresholding to mammograms obtained circa BBD diagnosis, we generated quantitative 
tissue composition metrics and determined their association with future invasive breast 
cancer diagnosis. Archival breast biopsies and mammograms were obtained for women 
(18-86 years of age) in a case-control study, nested within a cohort of 15,395 BBD patients 
from Kaiser Permanente Northwest (1970-2012), followed through mid-2015. Cases 
(n=514) who developed incident invasive breast cancer and controls (n=514) were 
matched on BBD diagnosis age and plan membership duration. All statistical tests were 2-
sided. 
Results  
Increasing epithelial area on the BBD biopsy was associated with increasing breast cancer 
risk (Odds ratio [OR]Q4 vs Q1=1.85, 95% confidence interval [CI] = 1.13-3.04; Ptrend=0.02). 
Conversely, increasing stroma was associated with decreased risk in non-proliferative, but 
not proliferative, BBD (Pheterogeneity=0.002). Increasing epithelium-to-stroma proportion 
[ORQ4 vs Q1=2.06, 95% CI =1.28-3.33; Ptrend=0.002) and percent mammographic density 
(MBD) (ORQ4 vs Q1=2.20, 95% CI = 1.20-4.03; Ptrend=0.01) were independently and strongly 
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stroma proportion/high MBD had substantially higher risk than those with low epithelium-
to-stroma proportion/low MBD [OR=2.27, 95% CI = 1.27-4.06; Ptrend=0.005), particularly 
among women with non-proliferative (Ptrend=0.01) versus proliferative (Ptrend=0.33) BBD.  
Conclusion 
Among BBD patients, increasing epithelium-to-stroma proportion on BBD biopsies and 
percent MBD at BBD diagnosis were independently and jointly associated with increasing 
breast cancer risk. These findings were particularly striking for women with non-
proliferative disease (comprising approximately 70% of all BBD patients), for whom 
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 In the U.S., >70% of 1.6 million annual breast biopsies are benign (1, 2). Although 
one of the strongest breast cancer risk factors (3, 4), not all women with benign breast 
disease (BBD) will develop breast cancer. To date, conventional approaches for risk 
stratification in BBD patients rely on microscopic assessment of epithelial abnormalities on 
BBD biopsies to classify women as having non-proliferative disease or proliferative disease 
without or with atypia (4-6). Patients with non-proliferative disease (~70% of all BBD 
patients) are at minimal or no increased breast cancer risk (5). Proliferative diseases 
comprise ~30% of all BBD biopsies and these patients have an almost 2-fold increased risk 
of breast cancer, with even higher 4-fold increased risk in the presence of atypical 
hyperplasia (7). Notably, atypical hyperplasia diagnoses comprise only ~4% of all BBD 
patients and, in absolute terms, fewer breast cancers will occur in these women than in 
those with non-proliferative BBD (8). Thus, there is the need to uncover additional tissue 
biomarkers that can aid to further stratify BBD patients into different breast cancer risk 
categories.  
Microscopically, the normal breast is comprised of epithelial, stromal, and adipose 
tissue components (9). Although qualitative aberrations in epithelium underpin BBD-
related breast cancer risk (10), the role of quantitative variation is poorly understood. 
Moreover, it remains fundamentally unclear whether risks related to BBD are driven by 
aberrations in the epithelium alone or via a dynamic interplay involving the stroma (11). 
Women undergoing breast biopsy, and for whom concomitant mammograms are available, 
represent an important patient population for the integrated study of histologic and 
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Within a cohort of women diagnosed as having BBD within a general community 
health care plan, we leveraged supervised machine-learning (12) and computer-assisted 
thresholding (13) methods to quantify breast tissue composition on histological and 
radiological images, respectively. This approach facilitated our investigations of the 
independent and joint associations of quantitative tissue metrics present at the time of BBD 
diagnosis with risk of subsequent breast cancer development. 
 
Methods 
Study population and design  
We conducted a nested case-control study within a cohort of 15,395 women aged 18-86 
years who were biopsied for BBD within the Kaiser Permanente Northwest Region (KPNW) 
between 1970-2012, with follow-up through mid-2015. KPNW is a prepaid healthcare plan 
with >500,000 members with facilities in Washington and Oregon. About 82% of KPNW 
members are White, 5% Asian American, 5% Hispanic, 3% African American and 5% other 
ethnicities (14). Case-control definition, ascertainment, and selection have been described 
in detail (15). Cases were women with a BBD biopsy who subsequently developed invasive 
breast cancer ≥one year after the index BBD biopsy. Controls were women biopsied for 
BBD at the same time as the case who were alive but had not developed breast cancer 
during the same follow-up period as the corresponding case. Controls were selected using 
risk-set sampling and were individually matched to corresponding cases on age at BBD 
diagnosis (+/– 1 year) and plan membership duration. Data on breast cancer risk factors 
around the time of BBD diagnosis were manually abstracted from medical records (15). 
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College of Medicine, the Kaiser Permanente Northwest Biospecimen Review Committee 
and the National Institutes of Health (NIH) Office of Human Subjects Research (OHSR).  
 
Tissue block retrieval and analysis of digitized H&E-stained sections      
The most representative formalin-fixed paraffin-embedded tissue block upon which the 
final clinical diagnosis of BBD was based was retrieved for each patient and H&E-stained 
cut-sections were prepared. BBD lesions on H&E-stained slides were subsequently 
classified according to Dupont and Page criteria as normal/non-proliferative, proliferative 
without atypia, and atypical hyperplasia (3). Terminal duct lobular unit (TDLU) involution 
was visually assessed based on published criteria from the Mayo BBD cohort (16) as 
follows: none (<25% of TDLUs involuted), partial (25-74%), or complete (≥75%) 
involution.  
H&E-stained slides were scanned at high resolution (20×) using the Aperio digital 
slide scanner (Leica Biosystems Inc. Buffalo Grove, IL). Of the 1028 slides, 50 were 
unscannable due to quality control issues. A 22-datapoint script involving two randomly 
selected representative-images was trained by a pathologist (MA) with expertise in digital 
pathology to identify, segment, and quantify (in mm2) areas on each slide comprised of 
epithelium (6-datapoints), stroma (5-datapoints), and adipose tissue (11-datapoints) as 
shown on Figure 1. Training and centralized image analysis were performed masked to all 
patient characteristics. In reproducibility analysis, another pathologist (MAD) 
independently developed a 37-datapoint script to analyze a random sample of 185(~20%) 
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(Spearman’s rho=0.95, 0.97, and 0.98 for epithelium, stroma, and adipose tissue areas, 
respectively; Supplementary Table 1).  
Percent epithelium, stroma, and adipose tissue were calculated by dividing the 
absolute value of each histologic metric by total tissue area on the slide and multiplying by 
100. Given the documented biologic relevance of tumor-stroma ratio in the setting of 
cancer progression (17, 18), we sought to evaluate an equivalent feature in the context of 
BBD progression. Accordingly, we calculated the proportion of fibroglandular tissue (i.e. 
epithelium + stroma) on histology slides that was epithelium relative to stroma, i.e. 
histologic epithelium-to-stroma proportion (histologic-ESP), by dividing epithelial area by 
total fibroglandular tissue area and multiplying by 100.  
 
Mammogram retrieval and mammographic breast density assessment   
The most recent mammograms occurring approximately 6 months before (preferably) or 
up to 1 month after the BBD biopsy were retrieved. Craniocaudal film mammographic 
views of the ipsilateral (preferable; 89%) or contralateral (11%) breast were digitized 
using an Array Corporation 2095 Laser Film Digitizer (Roden, the Netherlands; optical 
density=4.0). Prior studies have demonstrated high within-woman concordance for density 
measures and have found MBD to be predictive of risk irrespective of laterality (19). 
Quantitative measures of density were obtained using Cumulus®, an interactive computer-
assisted thresholding program (20), with demonstrated validity with respect to breast 
cancer risk associations in numerous epidemiologic studies (21). All mammograms were 
evaluated by a single expert reader (EAB), who measured absolute dense area (cm2) and 
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dividing the dense breast area by the total breast area and multiplying by 100 (Figure 1).  
Images from cases and matched controls were assessed within the same batch and in 
random order.  A repeat set of 113 images was assessed for reliability.  The intra-class 
correlation coefficients for percent MBD, dense area, and total breast area were 0.92, 0.89, 
and 0.99, respectively, documenting excellent reproducibility.   
 
Statistical analysis    
Associations between baseline patient characteristics and tissue composition metrics were 
assessed in multivariable linear regression models fitted to controls.  Locally weighted 
scatter plots of log residuals after regressing BMI and histology were used to demonstrate 
the distributions of tissue composition metrics by age among cases and controls. Quartiles 
(Q1-Q4) of tissue composition metrics were defined based on their distributions among 
controls. Associations between tissue composition metrics and breast cancer risk were 
assessed in crude and adjusted logistic regression models. For histologic metrics, 
conditional logistic regression models were adjusted for age at menarche, parity and age at 
first live birth, BMI, menopausal status/menopausal hormone therapy use, bilateral 
oophorectomy, history of breast cancer in a first degree relative, BBD histology, extent of 
lobular involution, calendar year of BBD diagnosis, as well as MBD. We used a likelihood 
ratio (LR) test to compare fit of a fully adjusted model with epithelium to one with 
histologic-ESP. As radiologic tissue metrics were less complete for cases and controls, we 
used unconditional logistic regression, adjusting for matching factors (age at BBD diagnosis 
and follow-up duration), other risk factors noted above, as well as histologic-ESP, which 
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MBD, both variables were dichotomized based on their median values among controls and 
a composite variable combining both was defined. Missing covariate values 
(Supplementary Table 2) were imputed using the multiple (×5) imputation by chained 
equations (MICE) approach (22) with appropriate variance adjustment by Rubin’s Formula 
(23) for all analyses. All analyses were performed overall and stratified by BBD histological 
classification. P-trend was estimated by including quartiles of tissue composition metrics as 
continuous variables in multivariable models. P-values for heterogeneity were obtained by 
including multiplicative interaction terms between BBD histology and relevant risk factors 
in the full model. All analyses were two-sided and were performed using Stata statistical 
software version 16.1. A P value of less than 0.05 was considered statistically significant.  
 
Results  
Characteristics of benign breast disease (BBD) patients at baseline  
A total of 514 cases and 514 controls (n=1,028 patients) with BBD were included in this 
study. Of these, >95% (488 controls, 486 cases) had an H&E suitable for digitized pathology 
assessment, with a single image failing analysis. For radiologic metrics, a total of 302 
(58.8%) controls and 296 (57.6%) cases had mammograms available within an average of 
1.3 (SD=3.5) months of BBD diagnosis. Most of the missing mammograms were for women 
diagnosed with BBD in the pre-screening (<1985) era. For those with BBD diagnosed in 
1985 or thereafter, >85.0% of cases and controls had available mammograms for MBD 
assessment. In total, 564 patients (284 controls and 280 cases) had data on both histologic 
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differ between those with available or missing histologic metrics (Supplementary Table 
3). For radiologic metrics, differences were mostly related to screening availability by 
calendar period (Supplementary Tables 3 and 4). The median (range) age of patients at 
BBD diagnosis was 51.5 (18.7-86.6) years. BBD lesions were predominantly non-
proliferative (68.9%), with fewer (27.9%) proliferative disease and atypical hyperplasia 
(3.2%). The distributions of other patient baseline characteristics are shown in Table 1.  
 
Tissue composition metrics in relation to patients’ baseline characteristics 
The median (range) of percent epithelial, stromal, adipose tissue and histologic-ESP 
distributions were 8.4% (0.2%-97.4%), 38.1% (1.3%-88.9%), 48.0% (1.3%-97.5%), and 
19.9% (0.9%-98.6%), respectively. Medians (ranges) for absolute dense and non-dense 
areas and percent MBD, were 36.3cm2 (0-232.2cm2), 96.4cm2 (5.9-375.5cm2), and 30.2% 
(0.0%-86.9%), respectively (Supplementary Table 5). The correlations between 
histologic and radiologic tissue composition metrics and their associations with baseline 
patient characteristics are provided in Supplementary Tables 6 and 7, respectively.  
As shown in Figure 2, the fat component of the breast was higher in older than 
younger women at the time of BBD diagnosis and among controls than cases across all age 
groups. In contrast, the fibroglandular tissue component was higher in younger than older 
women at BBD diagnosis and among cases than controls across all age groups. The amount 
of stroma did not differ between cases and controls under 60 years. Above 60 years, 
controls had higher stromal content than cases. Histologic-ESP was higher among cases 
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Associations between histologic metrics and breast cancer risk 
The median (range) time between BBD diagnosis and breast cancer incidence was 9 (1.5-
38.5) years. As shown in Table 2, increasing epithelial content on BBD biopsies was 
associated with increasing breast cancer risk (ORQ4 vs Q1=1.85, 95%CI = 1.13-3.04; -
trend=0.02), irrespective of BBD histology (P-heterogeneity=0.74). Conversely, the 
association between stroma and breast cancer risk differed by BBD histology (P-
heterogeneity=0.002). Among women with non-proliferative disease, increasing stroma 
was associated with decreasing breast cancer risk (ORQ4 vs Q1=0.51, 95% CI = 0.32-0.81; P-
trend=0.006), whereas among those with proliferative disease it was associated with 
increasing risk (ORQ4 vs Q1=2.52, 95% CI = 1.00, 6.32; P-trend=0.07). Histologic-ESP (LRχ2 
=8.4; P=0.03) provided better model fit than epithelium (LRχ2 =7.4; P=0.06) and was 
associated with statistically significant increased risk of breast cancer (ORQ4 vs Q1=2.06, 95% 
CI = 1.28, 3.33; P-trend=0.002), irrespective of BBD histology (P-heterogeneity=0.52). 
Histologic-ESP remained associated with breast cancer risk (ORQ4vsQ1=2.10, 95% CI = 1.33-
3.32; P-trend=0.002) even after adjusting for specific BBD histologic features.   
 
Associations between radiologic metrics and breast cancer risk 
As shown in Table 3, increasing percent MBD was associated with increasing risk of breast 
cancer (ORQ4 vs Q1=2.20, 95% CI = 1.20-4.03; P-trend=0.01), irrespective of BBD histology 
(P-heterogeneity=0.75).  
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Following dichotomization at their median values among controls, high histologic-ESP and 
percent MBD remained statistically significantly associated with elevated breast cancer risk 
(OR=1.57 [95% CI = 1.13-2.18]and 1.50 [95% CI = 1.01-2.24], respectively) (Table 4). 
Further, patients with high histologic-ESP had higher breast cancer risk than those with 
low histologic-ESP, irrespective of whether they had high (OR=2.06, 95% CI = 1.09-3.88) or 
low (OR=1.60, 95% CI = 0.93-3.88) MBD (Figure 3). Breast cancer risk was substantially 
higher in women with combined high histologic-ESP/high MBD than in those with low 
histologic-ESP/low MBD (OR=2.27, 95% CI = 1.27-4.06; P-trend=0.005). These findings 
were stronger in patients with non-proliferative (OR = 2.43, 95% CI = 1.20-4.93) versus 
proliferative (OR = 1.55, 95% CI = 0.45-5.33) disease, though statistically significant 
heterogeneity was not observed (P-heterogeneity=0.73).  
In analysis evaluating the potential value of histologic-ESP and MBD in predicting 
subsequent breast cancer, we calculated area under the receiver operating characteristics 
curves (AUCs); we found AUCs of 0.587, 0.607, 0.610, and 0.624 for BBD histology alone, 
BBD histology+histologic-ESP, BBD histology+MBD, and BBD histology+histologic-
ESP+MBD, respectively, suggesting incremental value for these metrics in predicting 
subsequent breast cancer.    
In sensitivity analyses, both histologic-ESP and percent MBD were associated with 
elevated breast cancer risk before and after multiple imputation and irrespective of 
menopausal status, BBD-to-tumor laterality, calendar period of BBD diagnosis, or time 
from BBD diagnosis to cancer development. Although histologic-ESP more strongly 
predisposed to ER-positive (ORQ4 vs Q1=1.71, 95% CI = 1.10-2.68; P-trend=0.009) than ER-
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Q1=2.08, 95% CI = 1.25-3.44; P-trend=0.002) than low-grade (ORQ4 vs Q1= 1.25, 95% CI = 
0.65-2.39; P-trend=0.41) tumors, differences by these tumor characteristics were not 
statistically significant.  
 
Discussion  
To our knowledge, this is the first study to combine machine-learning and computer-
assisted thresholding methods in the setting of BBD for histologic and radiologic 
assessments of tissue composition metrics, respectively, and to simultaneously relate these 
to breast cancer risk. We found statistically significant relationships of histologic-ESP, a 
metric of the proportion of fibroglandular tissue on breast biopsies that is epithelium 
relative to stroma, and percent MBD, a metric of the proportion of total tissue area on 
mammograms that is radiodense, with risk of breast cancer development. Histologic-ESP 
and percent MBD were independently associated with risk; women with combined high 
histologic-ESP/high MBD had substantially higher breast cancer risk than those with low 
histologic-ESP/low MBD. The association between increasing stroma and breast cancer 
risk varied by the extent of epithelial hyperplasia; increasing stroma was associated with 
reduced risk in women with non-proliferative disease and increased risk in those with 
proliferative disease. This finding has not been reported previously and suggests a possible 
dual role of the stroma in mediating progression of breast precursor lesions. These results 
were robust to adjustments for other breast cancer risk factors. Taken together, our 
findings provide new insights into breast cancer development following BBD and could 
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with BBD, particularly those with non-proliferative disease, a large group for whom 
relevant predictive biomarkers are lacking.  
To date, apart from BBD histological classification, very few risk factors for breast 
cancer have been identified for women with BBD. A few studies have reported the potential 
value of immunohistochemical (IHC) markers, including ER and/or PR expression, Ki-67 
and CD20 in predicting risk, but these have yet to be consistently validated (24-27). Other 
reports support the value of TDLU involution in predicting breast cancer development 
following BBD (16, 28-30). However, these studies have largely been based on qualitative 
assessments of involution, with limited stratification. Although standardized measures of 
involution have been proposed (30), these are difficult to obtain and rely on the availability 
of “normal”, non-lesional tissue regions on BBD biopsies. Our findings of independent 
relationships of histologic-ESP and percent MBD with increasing breast cancer risk 
demonstrate the potential for these quantitative markers to improve risk stratification for 
BBD patients. Notably, histologic-ESP is a tissue-based feature that can easily be assessed 
on the same H&E slides used for BBD diagnosis, without requiring IHC or other special 
stains. Accordingly, measures of histologic-ESP on BBD diagnostic H&E slides can be 
combined with MBD around the time of BBD diagnosis to provide additional information to 
women regarding their future breast cancer risk, at minimal or no extra cost or effort.  
Despite experimental evidence to support a context-dependent role of stroma to 
either prevent or promote carcinogenesis (31-36), the precise sequence and timing of 
events leading to a switch in stromal function from anti- to pro-tumorigenesis remains 
poorly understood. The prevailing model for BBD progression to cancer is that of a 
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proliferative disease (without atypia), atypical hyperplasia, in-situ carcinoma, and, 
ultimately, invasive breast cancer (37). Alternative pathways leading directly from 
normal/non-proliferative disease to invasive carcinoma have long been suspected (37), but 
specific tissue culprits are yet to be identified. Our finding of increasing breast cancer risk 
with increasing histologic-ESP that was particularly strong in women with normal/non-
proliferative BBD supports an alternative model involving aberrations in both epithelial 
and stromal compartments that favor carcinogenesis (Figure 4). In our proposed model, 
the transition from normal/non-proliferative to proliferative BBD is characterized by the 
loss of stromal protective effect as well as by a “proliferative-switch” in stromal function 
from tumor-suppressor to tumor-promoter. 
An important aspect in the clinical management of women with BBD or high MBD is 
to decide who is at sufficiently high risk to benefit from preventative strategies, such as 
chemoprevention, that reduce risk of developing cancer. Available risk prediction tools 
(38-43) have modest discriminatory accuracy, which could be improved by adding 
quantitative tissue composition metrics such as histologic-ESP and percent MBD.  
Furthermore, as >43% of screened U.S. women have dense breasts (44), it is imperative to 
identify additional factors that may identify those at high risk of invasive disease, requiring 
further clinical management (45, 46). In the current study, high histologic-ESP portended 
elevated breast cancer risk for women with low or high MBD, buttressing the importance of 
integrating histologic measures, when available, for distinguishing relative proportions of 
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Our application of machine-learning to digitized H&E slides allowed us to perform 
centralized analysis of all images using a single script, thereby limiting subject-specific bias 
and random error. The correlation between different scripts that were independently 
trained by two pathologists was excellent. This study is, however, not without limitations: 
most patients in this analysis underwent excisional biopsies, which have been largely 
replaced by needle biopsies as the standard of care. Also, there were too few women with 
atypical hyperplasia to allow for separate analysis. A primary goal of this analysis was to 
examine interrelationships between radiologic and histologic metrics with risk among BBD 
patients, and we did not have sufficient sample size to further refine MBD cut-points 
beyond the median value, which may have led to underestimation of risk estimates. Future 
work involving larger samples sizes that also integrate more contemporary approaches, 
including artificial intelligence (47), for density assessment on digital mammography will 
be important for extending the present findings.  
In summary, quantitative assessments of histologic-ESP on diagnostic BBD biopsy 
slides and percent MBD on mammograms performed around the time of BBD diagnosis 
were associated with increasing risk of subsequent invasive breast cancer development, 
particularly for women with non-proliferative disease. Furthermore, histologic-ESP 
identified women with low MBD who were at elevated risk of breast cancer and those with 
high MBD who were not. We also uncovered a context-dependent role of the stroma to 
either decrease or increase breast cancer risk in women with non-proliferative versus 
proliferative disease, respectively. Taken together, these findings provide clues regarding 
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Table 1: Baseline characteristics of the benign breast disease (BBD) patients, overall and by breast 
cancer case-control status, Kaiser Permanente Northwest Center for Health Research, 1970-2015 
 Characteristic 
Overall, No. (%) Controls, No. (%) Cases, No. (%) 
Pa 
(n = 1028) (n = 514) (n = 514) 
Median Age at BBD (range), years 51.5 (18.7-86.6) 51.4 (21.7-86.2) 51.5 (18.7-86.6) 0.97 
Median Follow-up time (range), years 9 (0.6-37.5) 9 (0.6-37.3) 9 (1-37.5) 1.00 
Age at menarche, years     
≤12 368 (45.5) 185 (44.6) 183 (46.5) 0.62 
13 245 (30.3) 132 (31.8) 113 (28.7)  
≥ 14 198 (24.2) 98 (23.6) 98 (24.9)  
Parity/age at first live birth     
Nulliparous/AFLB ≥30 y  225 (25.9) 98 (22.1) 127 (30.0) 0.008 
Parous/AFLB <30 y 643 (74.1) 346 (77.9) 297 (70.0)  
Body mass index, kg/m2     
<25  425 (45.8) 213 (45.8) 212 (45.8) 0.72 
25-30 281 (30.3) 136 (29.3) 145 (31.3)  
>30 223 (24.0) 116 (25.0) 107 (23.1)  
Family history      
Absent 791 (82.2) 408 (84.7) 383 (79.8) 0.04 
Present  171 (17.8) 74 (15.4) 97 (20.2)  
Menopause and MHT use     
Premenopausal  412 (43.4) 203 (41.9) 209 (45.0) 0.12 
Postmenopausal MHT use  393 (41.4) 211 (43.5) 182 (39.2)  
Postmenopausal No MHT  20 (2.1) 14 (2.9) 6 (1.3)  
Postmenopausal Unknown MHT  124 (13.1) 57 (11.8) 67 (14.4)  
Bilateral oophorectomy      
No 805 (86.3) 394 (83.8) 411 (88.8) 0.02 
Yes 128 (13.7) 76 (16.2) 52 (11.2)  
BBD histology     
Non-proliferative 708 (68.9) 384 (74.7) 324 (63.0) <0.001 
Proliferative, no atypia 287 (27.9) 124 (24.1) 163 (31.7)  
Atypical hyperplasia 33 (3.2) 6 (1.2) 27 (5.7)  
Sclerosing adenosis      
Absent 942 (91.6) 478 (93.0) 464 (90.3) 0.11 
Present  86 (8.4) 36 (7.0) 50 (9.7)  
Radial scar present      
Absent 977 (95.0) 497 (6.7) 480 (93.4) 0.01 
Present  51 (5.0) 17 (3.3) 34 (6.6)  
Fibroadenoma      
Absent 878 (85.4) 439 (85.4) 439 (85.4) 0.74 
Simple 133 (12.9) 68 (13.2) 65 (12.7)  
Complex 17 (1.7) 7 (1.4) 10 (2.0)  
Columnar cell hyperplasia     
Absent 875 (85.5) 450 (87.9) 425 (83.0) 0.03 
Present  149 (14.6) 62 (12.1) 87 (17.0)  
Lobular involution      
Absent 475 (52.5) 235 (52.8) 240 (52.2) 0.09 
Partial 176 (19.5) 75 (16.9) 101 (22.0)  
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a P values comparing cases and controls were obtained from chi-squared tests (for categorical 
variables) and Kruskal-Wallis test (for continuous variables). AFLB: Age at first live birth; MHT: 
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Table 2: Odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between histologic tissue composition metrics and risk 
of subsequent breast cancer development among women with BBD, overall and by BBD histological classificationa 
Histologic tissue metricsb 
Overall Non-proliferative Proliferative 
P het Controls/Cases OR (95% CI) Controls/Cases OR (95% CI) Controls/Cases OR (95% CI) 
Epithelium area (%)               
Quartiles               
Q1 (<4.45) 122/103 1.00 (reference) 100/83 1.00 (reference) 22/20 1.00 (reference) 0.74 
Q2 (4.45-7.93) 122/111 1.10 (0.72, 1.67) 100/78 1.02 (0.65, 1.62) 22/33 1.30 (0.52, 3.27)   
Q3 (7.93-14.36) 122/111 1.13 (0.72, 1.76) 90/64 0.97 (0.59, 1.57) 32/47 1.54 (0.64, 3.74)   
Q4 (>14.36) 122/161 1.85 (1.13, 3.04) 75/83 1.53 (0.93, 2.54) 47/78 1.90 (0.81, 4.47)   
P trend   0.02   0.16   0.15   
Per 10% increase  488/486 1.14 (0.99, 1.29) 365/308 1.14 (0.98, 1.29) 123/178 1.04 (0.86, 1.22)   
P value    0.06   0.08   0.64   
Stroma area (%)               
Quartiles                
Q1 (<24.66) 122/134 1.00 (reference) 83/94 1.00 (reference) 39/40 1.00 (reference) 0.002 
Q2 (24.66-38.08) 122/107 0.62 (0.40, 0.95) 85/59 0.48 (0.29, 0.79) 37/48 1.09 (0.52, 2.27)   
Q3 (38.08-53.70) 122/124 0.67 (0.43, 1.05) 87/68 0.48 (0.29, 0.79) 35/56 1.23 (0.61, 2.51)   
Q4 (>53.70) 122/121 0.71 (0.46, 1.11) 110/87 0.51 (0.32, 0.81) 12/34 2.52 (1.00, 6.32)   
P trend   0.16   0.006   0.07   
Per 10% increase  488/486 0.96 (0.87, 1.03) 365/308 0.88 (0.80, 0.97) 123/178 1.17 (1.01, 1.33)   
P value    0.24   0.01   0.03   
Adipose tissue area (%)               
Quartiles                
Q1 (<29.42) 122/135 1.00 (reference) 97/81 1.00 (reference) 25/54 1.00 (reference) 0.03 
Q2 (29.42-49.73) 122/132 0.99 (0.65, 1.51) 89/74 1.03 (0.65, 1.63) 33/58 0.86 (0.42, 1.76)   
Q3 (49.73-66.58) 122/99 0.81 (0.54, 1.21) 88/66 0.97 (0.61, 1.55) 34/33 0.44 (0.20, 0.96)   
Q4 (>66.58) 122/120 1.15 (0.73, 1.81) 91/87 1.61 (0.98, 2.64) 31/33 0.56 (0.23, 1.34)   
P trend   0.88   0.09   0.06   
Per 10% increase  488/486 1.01 (0.95, 1.08) 365/308 1.06 (0.99, 1.14) 123/178 0.93 (0.80, 1.06)   
P value    0.69   0.09   0.30   
Histologic-ESP (%)               
Quartiles                
Q1 (<10.82) 122/93 1.00 (reference) 109/97 1.00 (reference) 13/16 1.00 (reference) 0.52 
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Q3 (18.24-29.01) 122/131 1.58 (1.02, 2.45) 85/72 1.40 (0.89, 2.23) 37/59 1.41 (0.54, 3.66)   
Q4 (>29.01) 122/152 2.06 (1.28, 3.33) 72/80 1.95 (1.21, 3.16) 50/72 1.46 (0.57, 3.71)   
P trend   0.002   0.006   0.32   
Per 10% increase  488/486 1.15 (1.04, 1.27) 365/308 1.17 (1.06, 1.30) 123/178 1.00 (0.85, 1.15)   
P value    0.01   0.004   0.97   
a Benign breast disease (BBD) was classified as normal/non-proliferative and proliferative (with or without atypia).  
b Quartiles (Q1-Q4) of percent histologic tissue composition metrics (epithelium, stroma, adipose tissue, histologic epithelium-to-stroma 
proportion (histologic-ESP)) were defined based on their distributions among controls. In overall analyses, multivariate conditional 
logistic regression models adjusted for age at menarche, parity and age at first live birth, BMI, menopausal status/menopausal hormone 
therapy (MHT) use, bilateral oophorectomy, history of breast cancer in a first degree relative, BBD histology, extent of lobular involution, 
calendar year of BBD diagnosis, as well as MBD were used to estimate odds ratios (ORs) and corresponding 95% confidence intervals 
(CIs). In stratified analyses by BBD histology (i.e. non-proliferative disease and proliferative disease, with or without atypia), 
unconditional logistic regression models additionally adjusted for matching factors i.e. age at BBD diagnosis and follow-up time, were 
used to estimate ORs and 95% CIs. Epithelium and stroma were mutually adjusted for one another while histologic-ESP was additionally 
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Table 3: Odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between radiologic tissue composition metrics and 
risk of subsequent breast cancer development among women with BBD, overall and by BBD histological classificationa 
Radiologic tissue metricsb 
Overall Non-proliferative Proliferative 
P het Controls/Cases OR (95% CI) Controls/Cases OR (95% CI) Controls/Cases OR (95% CI) 
Absolute dense area (cm2)               
Quartiles               
Q1 (<21.87) 76/59 1.00 (reference) 54/36 1.00 (reference) 22/23 1.00 (reference) 0.84 
Q2 (21.87-35.54) 75/79 1.21 (0.71, 2.06) 54/41 0.99 (0.52, 1.91) 21/38 2.05 (0.79, 5.34)   
Q3 (35.54-58.94) 75/89 1.28 (0.75, 2.17) 50/49 1.34 (0.69, 2.59) 25/40 1.16 (0.45, 2.98)   
Q4 (>58.94) 76/69 1.14 (0.66, 1.95) 59/42 1.09 (0.57, 2.09) 17/27 1.23 (0.41, 3.67)   
P trend   0.50   0.46   0.99   
Per 10cm2 increase 302/296 1.02 (0.96, 1.07) 217/168 1.02 (0.95, 1.09) 85/128 1.00 (0.88, 1.12)  
P value     0.58    0.61    0.95   
Absolute non-dense area 
(cm2)               
Quartiles                
Q1 (<59.98) 75/86 1.00 (reference) 56/48 1.00 (reference) 19/38 1.00 (reference) 0.22 
Q2 (59.98-101.24) 76/79 0.88 (0.53, 1.46) 54/43 0.94 (0.51, 1.73) 22/36 0.76 (0.27, 2.12)   
Q3 (101.24-164.69) 75/99 0.97 (0.56, 1.68) 53/55 1.12 (0.56, 2.22) 22/44 0.67 (0.21, 2.12)   
Q4 (>164.69) 76/32 0.27 (0.13, 0.54) 54/22 0.40 (0.17, 0.92) 22/10 0.11 (0.02, 0.54)   
P trend   0.002   0.08   0.01   
Per 10cm2 increase   302/296  0.95 (0.92, 0.99)  217/168 0.97 (0.94, 1.01) 85/128 0.88 (0.79, 0.96)    
P value   0.005  0.17  0.006  
Mammographic density (%)               
Quartiles               
Q1 (<14.67) 75/49 1.00 (reference) 53/31 1.00 (reference) 22/18 1.00 (reference) 0.75 
Q2 (14.67-28.39) 76/78 1.58 (0.94, 2.68) 50/39 1.48 (0.77, 2.86) 26/39 1.69 (0.66, 4.34)   
Q3 (28.39-43.76) 76/82 1.88 (1.10, 3.24) 61/45 1.52 (0.79, 2.93) 15/37 3.26 (1.14, 9.26)   
Q4 (>43.76) 75/87 2.20 (1.20, 4.03) 53/53 2.29 (1.09, 4.83) 22/34 1.81 (0.56, 5.93)   
P trend   0.01   0.04   0.21   
Per 10% increase  302/296 1.12 (1.01, 1.23) 216/168 1.10 (0.96, 1.23) 85/128 1.15 (0.94, 1.37)   
P value   0.03   0.15   0.16   
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b Quartiles (Q1-Q4) of radiologic tissue composition metrics (absolute dense area (cm2), absolute non-dense area (cm2), percent 
mammographic breast density (MBD) (%)) were defined based on their distributions among controls. Overall and in women with non-
proliferative or proliferative disease (with or without atypia), unconditional logistic regression models were adjusted for age at menarche, 
parity and age at first live birth, body mass index, menopausal status/menopausal hormone therapy (MHT) use, bilateral oophorectomy, 
history of breast cancer in a first degree relative, BBD histology, extent of lobular involution, calendar year of BBD diagnosis, matching 
factors (age at BBD diagnosis and follow-up time from BBD to cancer), as well as histologic-ESP. Dense and non-dense areas were 
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Table 4: Odds ratios (ORs) and 95% confidence intervals (CIs) for the joint associations of epithelium-to-stroma proportion 
and percent MBD in relation to breast cancer risk among women with BBD, overall and by BBD histological classificationa 
Characteristic 
Overall Non-proliferative Proliferative 
controls/cases OR (95% CI) controls/cases OR (95% CI) controls/cases OR (95% CI) 
Binary categoriesb             
Histologic-ESP             
Low 244/203 1.00 (reference) 208/156 1.00 (reference) 36/47 1.00 (reference) 
High 244/283 1.57 (1.13, 2.18) 157/152 1.50 (1.08, 2.10) 87/131 1.37 (0.76, 2.45) 
P value    0.008   0.01   0.29 
MBD             
Low 151/127 1.00 (reference) 208/156 1.00 (reference) 36/47 1.00 (reference) 
High  151/169 1.50 (1.01, 2.24) 157/152 1.45 (0.87, 2.41) 87/131 1.73 (0.83, 3.59) 
P value    0.04   0.15   0.32 
Joint associations             
Low Histologic-ESP/low MBD 65/42 1.00 (reference) 57/32 1.00 (reference) 8/10 1.00 (reference) 
Low Histologic-ESP/high MBD 79/65 1.39 (0.78, 2.48) 65/47 1.60 (0.81, 3.13) 14/18 0.93 (0.24, 3.54) 
High Histologic-ESP/low MBD 75/80 1.53 (0.88, 2.67) 38/34 1.89 (0.95, 3.76) 37/46 0.82 (0.26, 2.63) 
High Histologic-ESP/high MBD 65/93 2.27 (1.27, 4.06) 44/48 2.43 (1.20, 4.93) 21/45 1.55 (0.45, 5.33) 
P trend   0.005   0.01   0.33 
a Benign breast disease (BBD) was classified as normal/non-proliferative and proliferative (with or without atypia). 
b Binary categories of histologic epithelium-stroma proportion (histologic-ESP) and mammographic density (MBD) were defined based on 
the median values among controls (i.e. 18.2% and 28.4%, respectively). Models were adjusted for BBD histology, lobular involution, 
Menopause/menopausal hormone therapy (MHT) use, history of bilateral oophorectomy, parity and age at first full term live birth, age at 
menarche, family history of breast cancer in a first degree relative, body mass index , MBD (for histologic-ESP), histologic-ESP (for MBD), 
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Figure legends 
Figure 1: Quantitative assessment of breast tissue composition metrics from 
digitized histological and radiological images. Supervised machine-learning and 
computer-assisted thresholding methods were applied to histologic (A and B) and 
radiologic (C and D) images from women with benign breast disease (BBD), respectively. 
Diagnostic hematoxylin and eosin (H&E) stained slides were digitized for image analysis 
while mammograms performed around the time of BBD diagnosis (average 1.3 months) 
were retrieved and digitized for analysis.  H&E image analysis was performed using the 
commercially available Halo version 1.2 Tissue Classifier algorithm (Indica Labs, 
Albuquerque, New Mexico), which is a random forest algorithm that is specifically designed 
for the identification and classification of tissue types based on color, texture and other 
contextual features. For training purposes, a representative H&E image was randomly 
selected, and the machine was trained to identify areas of epithelium (red), stroma (green), 
and adipose tissue (yellow). Panel A is an example of an H&E image before analysis. In 
panel B, the machine learns-by-example to accurately classify and quantify epithelial (red), 
stromal (green), and adipose tissue (yellow) areas. Panels C and D are examples of 
representative mammograms that were determined to have low (below the median 
distribution among controls) and high (above the median) percent mammographic breast 
density based on quantitative assessment using the Cumulus software interface.   
Figure 2: Histologic and radiologic breast tissue composition metrics by age and 
case-control status. Locally weighted scatter plot smoothing of log residuals (Y-axes) from 
linear regression models of non-dense area (A), dense area (B), and percent 
mammographic breast density (C), epithelium (D), stroma (E) and epithelium-to-stroma 
proportion (F). The effects of body mass index and benign breast disease histology on 
breast tissue composition were accounted for by adjusting for these in the linear regression 
models and plotting the log residuals against age.       
Figure 3: Joint associations of histologic epithelium-to-stroma proportion 
(histologic-ESP) and mammographic breast density (MBD) and risk of subsequent 
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Histologic epithelium-to-stroma proportion (ESP) and percent mammographic breast 
density (MBD) were dichotomized at their median values among controls (i.e. 18.2% and 
28.4%, respectively). Unconditional logistic regression models were adjusted for age at 
menarche, parity and age at first live birth, body mass index, menopausal 
status/menopausal hormone therapy use, bilateral oophorectomy, history of breast cancer 
in a first degree relative, benign breast disease (BBD) histology, extent of lobular 
involution, calendar year of BBD diagnosis, as well as  matching factors (age at BBD 
diagnosis and follow-up time from BBD to cancer). Analyses were performed overall 
(controls/cases (n) = 284/280) and among BBD patients with non-proliferative disease 
(NPD; controls/cases (n) = 204/161) and (C) proliferative disease (PD (with 
(w)/without(wo) atypia); controls/cases (n) = 80/119). Detailed odds ratios and related 
estimates are presented in Table 4. P values for trend (P-trend) were assessed by 
modelling the joint ESP/MBD variable as continuous in the multivariable model. P value for 
heterogeneity (P-het) was obtained by including a multiplicative interaction term between 
the joint ESP/MBD variable and BBD histology in the overall, fully adjusted, model. All tests 
were two-sided.  
Figure 4: Conceptual model of benign breast disease (BBD) to breast cancer 
progression incorporating the contributions of histologic changes in epithelium, 
stroma, and epithelium-to-stroma proportion to breast cancer risk. Increasing 
epithelium-to-stroma proportion (ESP) is displayed vertically, from bottom to top, to 
correspond to observed association with increasing risk of subsequent breast cancer 
development in this study (Table 2). The context-dependent role of the stroma to either 
inhibit or promote tumor formation in the setting of non-proliferative or proliferative 
disease (Table 2), respectively, is displayed horizontally. In this conceptual model of 
benign breast disease (BBD) to breast cancer progression, we propose that the proportion 
of the epithelial and stromal components of the breast is in a delicate balance during 
normal homeostasis. Disruption of this balance, either through uncontrolled epithelial 
proliferation arising from endogenous and/or exogenous factors, lack of age-related 
epithelial involution, or via exogeneous and/or endogenous causes of stromal depletion, 
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